Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
We always recommend that you speak with your OB-GYN or midwife before adding any new supplement to your routine
Wahidin Sudirohusodo Hospital in Makassar, and the Universitas Sumatera Utara Teaching Hospital in Medan
MEDVi MEDVi differentiates through fast approval times and included laboratory work
Eli Lilly and Company (Strongest obesity pipeline globally) Orforglipron Mechanism: Oral GLP-1 agonist (non-peptide) Expected approval: 2026 Major advantage: cheaper manufacturing, no injection Retatrutide Mechanism: GLP-1 + GIP + Glucagon Stage: Phase 3 Weight loss: up to ~29% Expected launch: 20262027 Eloralintide Amylin agonist (potential combo with GLP-1) Stage: Phase 2 3
Severe or prolonged gastrointestinal symptoms warrant medical review to rule out complications such as gastroparesis or pancreatitis, though these are rare
US$ 22.88
US$ 25.62
US$ 29.37
US$ 27.55
US$ 22.66
